Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
0.6830
-0.0512 (-6.97%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Celularity Employees
Celularity had 115 employees as of December 31, 2025. The number of employees decreased by 8 or -6.50% compared to the previous year.
Employees
115
Change (1Y)
-8
Growth (1Y)
-6.50%
Revenue / Employee
$230,870
Profits / Employee
-$798,261
Market Cap
19.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 115 | -8 | -6.50% |
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Daré Bioscience | 24 |
| Atossa Therapeutics | 16 |
| Werewolf Therapeutics | 14 |
| Tvardi Therapeutics | 12 |
| Cellectar Biosciences | 11 |
| Allarity Therapeutics | 8 |
| Neuphoria Therapeutics | 8 |
CELU News
- 6 weeks ago - Penny Stocks: Why Is Celularity (CELU) Stock Trending Today? - TipRanks
- 2 months ago - Celularity announces cenplacel-L availability for investigational use in Florida - TheFly
- 2 months ago - Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - GlobeNewsWire
- 2 months ago - Celularity Releases CEO Letter to Shareholders - GlobeNewsWire
- 2 months ago - Celularity Appoints Rick Gonzalez as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 3 months ago - Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - GlobeNewsWire
- 3 months ago - Celularity Annual report: Q4 2025 - Filings